Alnylam Pharmaceuticals announced it has completed enrollment in its Phase 2 clinical trial with revusiran.Merrimack Pharmaceuticals announced the U.S. FDA has granted orphan drug designation for the treatment of pancreatic cancer.

GlobeImmune IPO’d in June to little fanfare and has underperformed the biotech sector considerably since then. A key driving event in the next six months should put it back on the radar.

Alnylam posts positive phase 2 results in open-label study.

U.S. stocks slumped, with the Standard & Poor’s 500 Index falling below its 200-day average, as investors weighed prospects for Federal Reserve interest rate increases and slowing global economic growth.

December E-mini S&Ps (ESZ14 -0.05%) this morning are down -0.01% and European stocks are up +0.41%.

Rxi Pharmaceuticals stands to impress with anti-scarring results